Day

January 19, 2023

19
Jan
2023

From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run

Today’s guest on The Long Run is Jeb Keiper. Jeb is the CEO of Boston-based Nimbus Therapeutics. Nimbus made news in December 2022 when it sold its experimental Tyk2 inhibitor to Takeda Pharmaceuticals for $4 billion upfront and $2 billion in potential milestones. The drug’s value skyrocketed when it hit the primary endpoint of a Phase 2b clinical trial for...
Read More